Yes, slide 14 was very encouraging proof that BETonMACE is being performed in a diabetic (glucose, HbA1c%), low-HDL (HDL-C, apo-AI) population with increased inflammation (hsCRP, NLR). Just to clarify, those values in slide 14 are listed as the median, not the mean/average. Some of those clinical markers had a very large range in the min/max values, so hard to predict where the mean/average will end up. Also, certain clinical markers (fibrinogen, apo-AI, hsCRP) were only performed in ~400 of the patients, whereas the others clinical markers were done in closer to 2000 patients. Hopefully when all is said and done, we will have full data for all patients both at baseline and end of study.

BearDownAZ